Nonsense variant of NR0B1 causes hormone disorders associated with congenital adrenal hyperplasia

Da-Bei Fan1,3*, Li Li2,3 & Hao-Hao Zhang1

Congenital adrenal hyperplasia (CAH) is a rare X-linked recessive inherited disease that is considered a major cause of steroidogenesis disorder and is associated with variants or complete deletion of the NR0B1 gene. The DAX-1 protein (encoded by NR0B1) is a vertebrate-specific orphan nuclear receptor and is also a transcriptional factor for adrenal and reproductive development. CAH usually causes adrenal insufficiency in infancy and early childhood, leading to hypogonadotropic hypogonadism in adulthood; however, few adult cases have been reported to date. In this study, we examined a Chinese family with one adult patient with CAH, and identified a putative variant of NR0B1 gene via next-generation sequencing (NGS), which was confirmed with Sanger sequencing. A novel nonsense variant (c.265C>T) was identified in the NR0B1 gene, which caused the premature termination of DAX-1 at residue 89 (p.G89*). Furthermore, mutant NR0B1 gene displayed a partial DAX-1 function, which may explain the late pathogenesis in our case. Additionally, qPCR revealed the abnormal expression of four important genes identified from ChIP-seq, which were associated with energy homeostasis and steroidogenesis, and were influenced by the DAX-1 mutant. In addition, hormone disorders can be caused by DAX-1 mutant and partially recovered by siRNA of PPARGC1A. Herein, we identified a novel nonsense variant (c.265C>T) of NR0B1 in a 24-year-old Chinese male who was suffering from CAH. This mutant DAX-1 protein was found to have disordered energy homeostasis and steroidogenesis based on in vitro studies, which was clinically consistent with the patient’s phenotypic features.

There is growing evidence that congenital adrenal hypoplasia (CAH) is primarily caused by adrenal insufficiency and poses a serious threat to males1. CAH is a rare monogenic disorder that affects approximately 1/15,000 of live births. Recent advancements in sequencing techniques and bioinformatic tools have expanded our understanding of the molecular genetic basis and the variant spectrum of CAH. Various novel variants associated with CAH have been reported to date, suggesting that the identification of gene variants in CAH could be a promising approach to diagnose CAH2–4. Patients with this disorder usually show signs and symptoms of adrenal insufficiency in early infancy or throughout childhood. In contrast, recent studies have reported that patients with X-linked CAH show symptoms during late adolescence or even in adulthood5–7. Normally, the treatment for CAH includes lifelong glucocorticoid and mineralocorticoid replacement therapy8,9.

Most CAH cases follow an autosomal recessive or X-linked traits of inheritance1,3. Specific variants of the NR0B1 gene (the coding gene for the DAX-1 [dosage sensitive sex-reversal, adrenal hypoplasia locus on the X-chromosome, gene 1] protein), including point variants and delete variants, have been shown to cause X-linked CAH10,11. DAX-1 is an orphan nuclear hormone receptor that regulates adrenal development and functions as a dominant negative regulator of other nuclear receptors11. Moreover, DAX-1 encodes a protein of 470 amino acids, which is a member of the orphan nuclear hormone receptor superfamily and acts as a transcriptional repressor of genes involved in the steroidogenesis pathway12,13. The duplication of NR0B1 can cause a male-to-female sex reversal phenotype, while variants in NR0B1 lead to CAH associated with hypogonadotropic hypogonadism; this highlights the crucial role of DAX-1 in sex determination and gonadal development14,15. However, the biological role of DAX-1 mutant in patients with CAH remains unclear despite these aforementioned studies. A missense variant of DAX-1 (p.V385L) has been reported to be associated with nonobstructive azoospermia, indicating the important role of DAX-1 in spermatogenesis16. Numerous variants associated with CAH have been identified in the human NR0B1; few in-depth studies have uncovered the intricate molecular mechanism of the role of specific NR0B1 variants in CAH development.

1Endocrine Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 2Ophthalmologic Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 3These authors contributed equally: Da-Bei Fan and Li Li. *email: fccfandb@zzu.edu.cn
In the present study, we clinically examined a 24-year-old male affected with CAH from a three-generation family and identified a novel nonsense variant of the NR0B1 gene via next-generation sequencing (NGS). Furthermore, ChIP-seq analysis was performed to dissect several target genes such as CARTPT, PPARGC1A, PDE4B, and PDE4D, which led energy homeostasis and steroidogenesis to be associated with CAH for the first time. In addition, secreted hormones and related gene expression changes influenced by the DAX-1 mutant, which were partially recovered by silencing of PPARGC1A, implied that this NR0B1 variant caused CAH, providing a preliminary understanding of the potential molecular mechanism driving CAH. Taken together, these findings provide a preliminary understanding of the potential molecular mechanism driving CAH and significantly advance our molecular understanding of the varietal spectrum of NR0B1 in the context of CAH.

Materials and methods

Clinical examination. A Chinese family of Han ethnicity from Henan Province was identified and the family members were recruited for this study from the First Affiliated Hospital of Zhengzhou University (Fig. 1A). One 24-year-old male (46,XY karyotype) with CAH was physically and clinically examined to determine physical and clinical symptoms. His height and weight were 172.7 cm and 41.2 kg, respectively, and he appeared slightly emaciated. In addition, his blood pressure was 114/68 mmHg without medication. The medical history of the affected family members was also recorded. At least 100 unrelated healthy participants without endocrine diseases or other clinical diseases from Henan Province were chosen as healthy controls. Venous blood samples were collected from the proband and his family members and placed in tubes containing ethylenediaminetetraacetic acid (EDTA) for DNA isolation and NGS sequencing.

NGS and Sanger sequencing. Blood DNA was isolated from venous blood samples collected from patients using the QIAamp DNA Blood Mini Kit (Qiagen, USA) following standard protocols and then sent to BGI (Shenzhen, China) for exonic capture and panel re-sequencing. Library preparation was performed following standard protocols as described previously\(^1\). NimbleGen custom arrays, which enriched the exonic sequences of endocrine-related genes and other genes that have been shown to cause related steroidogenesis disorder, were used for the capture procedure. Furthermore, paired-end sequencing for 100-bp reads was performed on an Illumina HiSeq2000 platform (Illumina, USA).

Raw sequence reads were first filtered using Trim-Galore to export clean data, which was subsequently aligned to the human genome using the BWA program\(^1\). The quality of these clean reads was recalibrated by associated software, and then duplicated reads were removed using SAMtools\(^3\). Unique mapping reads were then applied for variation detection, and were annotated by RefSeq according to the manufacturer's recommendation. The variants retrieved from NGS were annotated using an in-house functional prediction tool and then compared with the dbSNP132 and the 1000 Genomes databases. One probable gene variant annotated to NR0B1 was acquired from our NGS results and was further verified by Sanger sequencing. PCR products were amplified using predesigned primers and purified with a commercial DNA fragment purification kit (Takara, Japan). These amplified PCR fragments were cloned into pUC19 and then analyzed by Sanger sequencing. The hydrophobicity of the resulting wild-type and mutant proteins was predicted using the online tool ProtScale (https://web.expasy.org/protscale/) on the ExPASy Server. Additionally, the 3D structure of wild-type and mutant DAX-1 protein was visualized and analyzed using the online tool SWISS-MODEL (https://swissmodel.expasy.org/\(^1\))

Cell culture and transfection. Human adrenal NCI-H295R cells were obtained from the American Type Culture Collection (ATCC) and cultivated in Dulbecco's modified Eagle's medium (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, USA). Cells were cultured at 37 °C in a humidified 5% CO₂
atmosphere supplied with penicillin and streptomycin (Gibco, USA). Before transfection, cells were seeded in a 24-well plate for 24 h. In total, 60 ng of WT or mutant DAX-1 plasmid was transfected into these seeded cells using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s standard protocols. In addition, siRNA of PPARγ1A and mutant DAX-1 plasmid were simultaneously transfected into seeded cells. Thereafter, positive transfected cells were screened and selected on plates containing DMEM supplemented with G418 for further experimental analyses.

Luciferase reporter assays. A human NR0B1 gene fragment was first amplified by PCR. Subsequently, the PCR fragments were purified and inserted into the pcDNA3.1 expression vector. Site-directed mutagenesis was performed to generate the DAX-1 mutant according to previous reports20. DNA sequencing was used to confirm the correct sequence of both the wild-type and variant.

The regulatory role of NR0B1 in modulating transcription was monitored using the StAR-luc plasmid (luciferase reporter plasmid) following the method outlined in a previous report21. Briefly, seeded cells were treated with 20 ng STAR-luc, 0.5 ng pRL-SV40, and 60 ng WT or mutant NR0B1. Next, 20 ng NR5A1 plasmid encoding SF-1 was added to the seeded cells using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s standard protocols. The luciferase activity in the transfected cells was determined using the Dual-Glo luciferase assay system (Promega, USA). Data were normalized to Renilla luciferase activity.

ChIP-seq assays. The ChIP-seq assay was performed by BGI (Shenzhen, China) to identify the genes associated with mutant DAX-1. In brief, cells treated with mutant DAX-1 were fixed with 1% formaldehyde for 5 min at room temperature and glycine was added to stop the crosslinking reaction. Cells were lysed in ChIP lysis buffer with a sonication system. After dilution with mixing buffer (20 mM Tris–HCl, 150 mM NaCl, 2 mM EDTA, and 1% Triton X-100), the sheared chromatin was subjected to immunoprecipitation with an anti-NR0B1 antibody (Abcam, USA). The immunoprecipitated DNA was then harvested and subjected to several washes with ChIP-RIPA buffer, high-salt ChIP-RIPA buffer, LiCl buffer, and finally TE buffer. Following treatment, the DNA fragments were purified using a commercial DNA purification kit. For ChIP-seq, ChIP-seq libraries were prepared using the NEBNext DNA sample prep master mix (NEB, USA) according to manufacturer’s protocol. After validating the quality of the library using a Bioanalyzer 2100 (Agilent, USA), the library was sequenced by NGS on an Illumina HiSeq2000 platform (Illumina, USA). Raw data were processed using Bowtie based on a human genome reference. Thereafter, the mapped reads were screened using Model-based Analysis for ChIP-seq (MACS) to identify ChIP-seq peaks and regions of NR0B1 enrichment.

qPCR assays. To determine the expression level of mutant DAX-1-associated genes, RNA was isolated from NCI-H295R transgenic or WT cells using the Qiagen RNeasy Mini Kit (Qiagen, USA) and then transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, USA). Quantitative real-time PCR (qPCR) was performed using TB Green Fast qPCR Mix (Takara, Japan) and conducted on a real-time PCR detection system (CFX96, Bio-rad, USA) according to previously mentioned protocols22. The relative expression levels of associated genes were determined by the 2−△△Ct method after normalization to the endogenous gene GAPDH. All of the primers used are listed in Supplementary Table 2.

Hormone determination assays. The activities of cellular or extracellular hormones, including progesterone, testosterone, 17β-estradiol, cytochrome P450 steroidogenic enzyme (SE) CYP11A1, follicle stimulating hormone (FSH), and luteinizing hormone (LH), were determined by enzyme-linked immunosorbent assay (ELISA) using purchased commercial kits following the manufacturers’ procedures.

Statistical analysis. All experiments in this study were performed to obtain at least three biological replicates, and the retrieved data are expressed as the mean ± SD (standard deviation of the mean). Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad, USA). The retrieved data were subjected to a Kruskal–Wallis one-way Analysis of Variance (ANOVA) to evaluate differences. Different lowercase letters on the bars of columns indicate the significance of differences at P < 0.05, while the same lowercase letters on the bars of columns indicate no significant differences at P > 0.05 (n.s.).

Ethics statement. This study was performed in accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of the First Affiliated Hospital at Zhengzhou University (Zhengzhou, China). The statement on informed consent (in both Chinese and English) was obtained from the patient and other participants. The statement on consent to publish the information in this study was obtained from the patient and other participants.

Results

Clinical evaluation of the patient with CAH. One Chinese family from Henan Province was recruited for this study. The pedigree of this family was plotted based on our clinical investigation, and revealed an X-linked recessive inheritance pattern. This family spans three generations, with five healthy living members and one family member living with CAH (Fig. 1A). We found that the proband, a 24-year-old male, presented with skin hyperpigmentation, fatigue, vertigo, nausea, emaciation, vomiting, and poor sleep according to a clinical examination and the patient’s description. The patient was diagnosed with typical signs of adrenal abnormality and precocious puberty at 20 years of age. The patient and his parents declared that there was no reported history of surgery or additional diseases. With the exception of these symptoms, our clinical evaluation found no
other pathologic findings that could account for the presence of endocrine disorders. In addition, the patient's hormone levels remained disordered after therapy with hydrocortisone and fludrocortisone. Specifically, his adrenotropic hormone levels were high (120 pg/mL), while the levels of testosterone (< 0.13 ng/mL), luteinizing hormone (0.09 U/mL), and renin (0.86 ng/mL) levels were found to be lower than normal, and potassium was in the normal range (4.08 mmol/mL). The patient's parents were non-consanguineous and reported no history of hypertension or recurrent episodes of periodic paralysis. In addition, none of the other family members suffered from other related endocrine or systemic syndromes.

Identification of a single novel nonsense variant in the patient with CAH. The exonic sequences of endocrine-related genes and other genes were captured and sequenced using genomic DNA obtained from blood samples. Nearly 539.72 Mb of raw data and 505.48 Mb of processed data were generated from our NGS results. More than 95% mean coverage of target regions was obtained in this NGS dataset, with an average sequencing depth of >400 ×. Furthermore, the coverage of target bases for the N10 and N20 reads from this dataset were 86.8% and 75.9%, respectively. One variant greater than 0.05 existed after filtration by minor allele frequency from an in-house Asia database. This was then validated by Sanger sequencing. In silico analysis revealed one novel nonsense variant in the NR0B1 gene that has not been previously reported or recorded. In this family, a nonsense variant was identified in the first exon of NR0B1 (c.265C>T), which resulted in the substitution of a conserved glutamine (Gln) with a stop codon (Ter) at codon 89 (p.Gln89*). We further sought to verify the occurrence of this variant in all affected members by Sanger sequencing (Fig. 1B). The mother and sister of the patient were heterozygotes for this variant, whereas the variant was absent in all unaffected male family members and also healthy controls. Accordingly, this novel variant was not reported in other studies. Additionally, this mutation was evaluated to be causative for CAH formation.

Bioinformatic assessment demonstrated that the NR0B1 variant was deleterious. It has been reported that the function and structure of DAX-1 can be influenced by a resultant truncated polypeptide caused by a variant. Therefore, we first evaluated the impaired structure of our variant using SWISS-MODEL. After simulation, we found that this novel variant disrupted the entire amino acid order so that the mutant structure could not be built using SWISS-MODEL. Additionally, nearly 81% of the structure was missing compared to wild-type DAX-1, implying that this variant could potentially disrupt the function of DAX-1. In addition, the hydrophobicity of wild-type and mutant DAX-1 predicted by Protscale demonstrated that this variant largely altered the hydrophobicity of mutant DAX-1 (Supplementary Figure 1). Collectively, the in silico data showed the deleterious impact of this novel variant, which has the potential to cause CAH.

Transcriptional initiation was suppressed by the NR0B1 variant. To investigate the influence of this nonsense variant on NR0B1 transcription, plasmids containing NR0B1 and its variant were transiently transfected into NCI-H295R cells. Relative NR0B1 expression levels were then determined by qPCR. As shown in Fig. 2, the NR0B1 expression levels in mutant DAX-1 cells were remarkably decreased compared to WT, whereas wild-type DAX-1 overexpression resulted in significant elevation of relative NR0B1 transcripts compared to con-
trol and mutant cells, suggesting that the in vivo transcriptional abundance of NR0B1 was suppressed due to this variant. This finding also demonstrated that mutant NR0B1 could suppress normal NR0B1 transcriptional levels.

Considering the crucial role of NR0B1 as a transcriptional factor that regulates the transcriptional activation of its target genes, we next sought to verify the transcriptional regulatory role of mutant DAX-1. DAX-1 has been proven to function as a negative regulator to suppress SF-1-mediated transactivation of steroidogenic genes, such as StAR. Hence, in this study, we performed luciferase assays to investigate the impairment of original DAX-1 function (Fig. 3). As expected, wild-type DAX-1 suppressed the relative luciferase activity, which was in accordance with the finding of a previous report. Intriguingly, mutant DAX-1 significantly improved luciferase activity compared to wild-type DAX-1, suggesting that this NR0B1 variant impaired the repressor function of DAX-1 during transcriptional regulation. Moreover, compared to the group without wild-type DAX-1, the luciferase activity of mutant DAX-1 was relatively lower, demonstrating that DAX-1 still had partial function with this novel variant.

Variant NR0B1 regulated several genes associated with body-metabolism. Although this nonsense variant of NR0B1 impaired self-transcriptional regulation based on the above data, the molecular mechanism underlying CAH remains obscure in this particular case. To this end, in order to further elucidate the influence of this NR0B1 variant on targeting genes, we performed ChIP-sequence analysis of NR0B1 variants with an anti-NR0B1 polyclonal antibody in NCI-H295R human adrenocortical tumor cells. After sequencing, we obtained numerous reads distributed in several chromosomes (Supplementary Figure 2). Moreover, numerous pathways were found to be perturbed in mutant DAX-1 compared to WT (Supplementary Figure 3 and 4). Four typical genes, including CARTPT, PPARGC1A, PDE4B, and PDE4D, were found to be closely related to NR0B1 as shown in Supplementary Table 1. Interestingly, the loci of these four genes were not near the loci of NR0B1, and, in some cases, were even from a different chromosome. Among these genes, CARTPT seems to have anorexigenic effects based on previous literature. To validate the regulation of CARTPT by DAX-1, qPCR was performed using the primers shown in Supplementary Table 2. As shown in Fig. 4A, the DAX-1 mutant caused CARTPT upregulation compared to wild-type DAX-1, which confirmed that this NR0B1 variant could mediate CARTPT upregulation. This may have caused anorexigenic effects for the patient, leading to emaciation, which was congruent with the patient’s clinical record. In addition, the relative transcript abundance of PPARGC1A gene (encoding peroxisome proliferator-activated receptor gamma coactivator 1 alpha), a potentially powerful coactivator of many transcriptional factors related to steroidogenesis, was then evaluated. As shown in Fig. 4B, the expression of PPARGC1A was upregulated by mutant DAX-1, which may have resulted in abnormal steroidogenesis and energy homeostasis, finally leading to CAH. Phosphodiesterases (PDEs) can regulate the intracellular levels of cAMP, the most important regulatory signaling molecule in the control of steroidogenesis, and can affect steroidogenesis. Our results confirmed that the expression of PDE4B and PDE4D was upregulated by mutant DAX-1 (Fig. 4C,D), which in turn, impaired steroidogenesis; this was consistent with the patient’s clinical data.

DAX-1 mutant stimulated hormone disorders. The hormone levels of our patient were abnormally expressed, which we speculated was caused by the nonsense variant. To test this, the changes in hormone levels
caused by the DAX-1 mutant were determined for several common hormones. As shown in Fig. 5, overexpression of wild-type \( NR0B1 \) (OE-WT) caused the downregulation of secreted hormones, including progesterone, testosterone, and 17B-estradiol, suggesting that wild-type \( NR0B1 \) expression caused this hormone change. Predictably, after overexpression of variant \( NR0B1 \) (OE-MUT), the levels of secreted hormones increased compared to those of the WT and OE-WT groups. In addition, the activities of StAR and SF-1 were enhanced by variant \( NR0B1 \) overexpression compared to the other two groups (Fig. 6A,B), demonstrating that mutant DAX-1 could directly regulate StAR and SF-1 in hormone disorders, which was in accordance with our hormone data in Fig. 5. Furthermore, the level of the cytochrome P450 steroidogenic enzyme CYP11A1 was significantly upregulated in OE-MUT (Fig. 6C), implying that our DAX-1 mutant regulated related target genes (such as \( PPARGC1A \) and \( PDEs \)), resulting in a disorder of steroidogenesis. It is well known that the unordered expression levels of FSH and LH are frequently detected in patients with CAH. Therefore, it became necessary to detect the corresponding hormones in cells overexpressing variant \( NR0B1 \). As expected, FSH and LH reached maximum values of 8.05 and 6.61 ng/mL in the OE-MUT line, respectively (Fig. 6D,E), which suggested that the high expression levels of FSH and LH were caused by this \( NR0B1 \) variant.

**PPARGC1A inhibition caused the recovery of hormone levels in the DAX-1 mutant.** The expression of \( PPARGC1A \), which was identified as being pivotal in steroidogenesis, was upregulated by variant \( NR0B1 \) based on our qPCR data. We also explored the related physiological parameters of variant \( NR0B1 \) by adding siRNA targeting \( PPARGC1A \). As expected, \( PPARGC1A \) expression levels were downregulated to the level of WT, suggesting that siRNA of \( PPARGC1A \) was successfully integrated into these cells to influence the expression of \( PPARGC1A \) (Fig. 7A). Intriguingly, the \( NR0B1 \) expression level was unchanged after the expression of siRNA of \( PPARGC1A \) (Fig. 7B). In addition, the expression of secreted hormones (Fig. 7C-E) was partially inhibited to a relatively low level by the siRNA of \( PPARGC1A \), confirming that variant \( NR0B1 \) regulates \( PPARGC1A \) to modulate hormone expression and secretion.
Discussion
In this study, for the first time, we identified a novel nonsense variant located in *NR0B1* with X-linked inheritance from a three-generation Han family by NGS analysis, which was further corroborated by Sanger sequencing (Fig. 1). Our data showed that the particular novel nonsense variant was co-segregated in a proband in this pedigree, while no such variant was observed in healthy male family members and other healthy individuals. These results demonstrate that this nonsense variant may be responsible for the CAH phenotype with X-linked inheritance in a Chinese Han family. It is well known that X-linked CAH is caused by a DAX-1 variant, which is encoded by *NR0B1* composed of two exons separated by one intron. Numerous additional variants have been identified since the discovery of *NR0B1* as the gene responsible for CAH. Currently, approximately 200 variants of *NR0B1* have been reported in patients with CAH, all of which alter the C-terminus of the DAX-1 protein. Among them, nearly 50% are frameshift variants, which cause the loss of the repressive functions of DAX-1. It has been reported that the truncated protein caused by in-dels might affect the transcriptional repression and post-transcriptional regulation of this gene, resulting in the occurrence of CAH. Interestingly, in this case, we identified a novel nonsense *NR0B1* variant in a Han population; this variant has a truncated protein lacking the C-terminal ligand binding domain, implying that the deleterious effects were due to the lack of this C-terminal ligand binding domain. This gene variant was predicted to cause crucial structural changes in the DAX-1 protein, with nearly 81% of the protein structure missing compared to wild-type DAX-1, thereby disrupting the function of mutant DAX-1. The loss of DAX-1 function triggered by this *NR0B1* variant caused disordered expression of genes involved in energy homeostasis and steroidogenesis, which may lead to abnormal adrenal development and finally CAH. These findings are in line with previous reports in this field.

Figure 6. The levels of typical transcriptional factor and hormone of transfected and non-transfected cells. (A) StAR, (B) SF-1, (C) CYP11A1, (D) FSH, and (E) LH. StAR: Steroidogenic acute regulatory protein, SF-1: Steroidogenic factor 1, CYP11A1: Cytochrome P450 steroidogenic enzyme CYP11A1, FSH: Follicle stimulating hormone, LH: Luteinizing hormone. Error bars represent the standard deviation from triplicate samples. Different lowercase letters represent the significance of differences at \( P < 0.05 \).

Figure 7. Biochemical characteristics of cells treated with siRNA of PPARGC1A. (A) Relative expression level of PPARGC1A and (B) NR0B1. (C) Secreted progesterone level, (D) secreted testosterone level, and (E) secreted 17B-estradiol. WT: Wild-type cells, OE-WT: Cells overexpressing normal NR0B1, MUT-siRNA: Cells overexpressing variant NR0B1 and siRNA of PPARGC1A. Error bars represent the standard deviation from triplicate samples. Different lowercase letters represent the significance of differences at \( P < 0.05 \).
To verify this notion with regards to the deleterious impacts of mutant DAX-1, functional analyses were performed to evaluate the consequences of this novel nonsense variant. The qPCR results shown in Fig. 2 demonstrate that overexpression of mutant DAX-1 significantly downregulated the expression of NR0B1 compared to WT, suggesting that mutant DAX-1 represses NR0B1 transcription in vivo.

It has been reported that DAX-1 plays a crucial role in steroid and hormone biosynthesis as a transcriptional factor. Related literature has shown that DAX-1 is a negative regulator that represses the SF-1 (steroidogenic factor 1)-mediated transactivation of various key genes related to steroidogenesis. Two such variants (Y380D and I439S) in DAX-1 were found to be located in the C-terminal region of the protein, and showed a partial repression activity of SF-1-mediated transcription. Rojek et al. demonstrated a novel hemizygous deletion encompassing the entire NR0B1 gene together with the MAGEB genes, which was associated with congenital adrenal insufficiency and normal development of male external genitalia. Intriguingly, a Q37X nonsense variant in DAX-1 has been reported to cause a truncated isoform of DAX-1 protein which exhibited partial residual activity, thereby delaying the onset of adrenal insufficiency until early adulthood. The current patient suffered from CAH from early adulthood, suggesting that this mutant DAX-1 possessed partial residual activity, which may have delayed the disorders of hormone biosynthesis in this patient. We next performed a luciferase assay to elucidate the effects of a mutant on the repressor function of DAX-1. As expected, mutant DAX-1 impaired the function of DAX-1 with a higher luciferase activity compared to WT, which demonstrated the abnormal regulation of mutant DAX-1 (Fig. 3). Numerous previous studies have focused on the traditional regulatory mechanism involving the DAX-1 mutant. To elucidate the molecular mechanism of this novel nonsense variant, we first performed ChIP-seq to identify target genes associated with mutant DAX-1. Interestingly, four crucial genes, including CARTPT, PPARGC1A, and PDE4, were found to be associated with mutant DAX-1. In addition, related secreted hormones and regulation factors were detected, suggesting that mutant DAX-1 caused disordered hormone and regulation factor expression (Figs. 5, 6). CARTPT encodes a preproprotein that is proteolytically processed to generate multiple biologically active peptides involved in appetite, energy balance, body weight maintenance, and stress response. Lack of CARTPT in mice has been shown to result in increased body weight, and viral delivery of CARTPT mRNA through the intracerebroventricular cannula suppressed weight gain in diet-induced obese rats. Interestingly, in our case, CARTPT was upregulated by the NR0B1 variant compared to WT, demonstrating that this mutant DAX-1 controlled the body weight via disordered CARTPT expression, which was in accordance with the findings of a pervious study. Moreover, knockdown of PPARGC1A inhibited the gene expression pattern related to testosterone synthesis, leading to disorders of testosterone secretion. Our ChIP-seq data revealed that PPARGC1A is a potential target gene related to NR0B1 that may finally lead to CAH. These findings suggest that NR0B1 variation triggered the disorder of coactivator PPARGC1A and led to unusual energy and testosterone metabolism, which was in accordance with our qPCR data (Fig. 4). Furthermore, we used siRNA of PPARGC1A to validate that knockdown of PPARGC1A mutant NR0B1 partially recovered hormone biosynthesis, implying that interference of PPARGC1A regulation could effectively recover cellular hormone stasis (Fig. 7). Additionally, two typical PDE genes, PDE4B and PDE4D, were found to be related to NR0B1, suggesting that abnormal expression of PDE genes influenced steroidogenesis and may cause CAH. It has been shown that inhibition of the enzymes PDE4 and PDE8 significantly increased testosterone levels in Leydig cells, which is in agreement with our data. Previous reports have already demonstrated that chronic ablation of PDEB8 increases cAMP-dependent transcription of several key steroidogenic proteins, such as StAR protein and p450scc. It is worth noting that the PDEs in this study were altered by the DAX-1 mutant to affect steroidogenesis, possibly by regulating StAR activity. Therefore, this is a worthwhile hypothesis for us to investigate in future research.

In conclusion, the present study identified a novel nonsense variant of NR0B1 that crucially regulated several targeted genes, causing inhibition of steroidogenesis, and finally leading to abnormal adrenal development. Our data provide novel insights into the potential mechanism of CAH formation caused by this nonsense variant. Additionally, our findings significantly advance the current understanding of the Chinese variation spectrum of CAH.

Received: 22 April 2020; Accepted: 19 July 2021
Published online: 09 August 2021

References
1. Speiser, P. W. & White, P. C. Congenital adrenal hyperplasia. New Engl. J. Med. 349, 776–788. https://doi.org/10.1056/NEJMra021561 (2003).
2. Iughetti, L. et al. Isolated hypoaldosteronism as first sign of X-linked adrenal hypoplasia congenita caused by a novel mutation in NR0B1/DAX-1 gene: A case report. RMC Med. Genet. 20, 98. https://doi.org/10.1186/s12519-019-0034-7 (2019).
3. Ge, J. & Li, T. A patient with DAX1 mutation presenting with elevated testosterone in early infancy. World J. Pediatr. 15, 309–311. https://doi.org/10.1007/s12519-019-00236-4 (2019).
4. Suthiworachai, C. et al. Identification and functional analysis of six DAX1 mutation in patients with X-linked adrenal hypoplasia congenita, J. Endocr. Soc. 3, 171–180. https://doi.org/10.1210/js.2018-00270 (2018).
5. El-Saouche, D., Arti, W. & Merke, D. P. Congenital adrenal hyperplasia. Lancet 390, 2194–2210. https://doi.org/10.1016/S0140-6736(17)31431-9 (2017).
6. Khattab, A. et al. Long term outcomes in 46, XX adult patients with congenital adrenal hyperplasia reared as males. J. Steroid Biochem. Mol. Biol. 165, 12–17. https://doi.org/10.1016/j.jsbmb.2016.03.033 (2017).
7. Reisch, N. Substitution therapy in adult patients with congenital adrenal hyperplasia. Best Pract. Res. Clin. Endocrinol. Metab. 29, 33–45. https://doi.org/10.1016/j.bcp.2014.11.002 (2015).
8. Girgis, R. & Winter, J. S. D. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin. Endocrinol. Metab. 82, 3926–3929. https://doi.org/10.1210/jcem.82.12.4320 (1997).
9. Padilela, R. & Hindmarsh, P. C. Mineralocorticoid deficiency and treatment in congenital adrenal hyperplasia. Int. J. Pediatr. Endocrinol. 2010, 656925. https://doi.org/10.1155/2010/656925 (2010).

10. Krone, N. et al. Thirteen novel mutations in the NR0B1 (DAX1) gene as cause of adrenal hypoplasia congenita. Hum. Mutat. 25, 502. https://doi.org/10.1002/humu.3393 (2005).

11. Rojek, A., Obara-Moszyńska, M., Malecka, E., Slomko-Józwiak, M. & Niedziela, M. NR0B1 (DAX1) mutations in patients affected by congenital adrenal hypoplasia with growth hormone deficiency as a new finding. J. Appl. Genet. 54, 225–230. https://doi.org/10.1007/s13353-013-0133-3 (2013).

12. Lehmann, S. G., Wurtz, J. M., Renaud, J. P., Sassone-Corsi, P. & Lalli, E. Structure–function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients. Hum. Mol. Genet. 12, 1063–1072. https://doi.org/10.1093/hmg/ddg108 (2003).

13. Clpphasis, R. & McCabe, E. R. B. DAX1 and its network partners: Exploring complexity in development.

14. Zheng, L., Baumann, U. & Reymond, J. L. An efficient one-step site-directed and site-saturation mutagenesis protocol.

15. Yu, T.

16. Mou, L.

17. Smyk, M.

18. Li, H.

19. Clipsham, R. & McCabe, E. R. B. DAX1 and its network partners: Exploring complexity in development.

20. Zheng, L., Baumann, U. & Reymond, J. L. An efficient one-step site-directed and site-saturation mutagenesis protocol.

21. Yu, T.

22. Ito, M., Yu, R. & Jameson, J. L. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita.

23. Rogge, G., Jones, D., Hubert, G. W., Lin, Y. & Kuhar, M. J. CART peptides: regulators of body weight, reward and other functions.

24. Ito, M., Yu, R. & Jameson, J. L. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita.

25. Qin, G., Ji, H., Li, X., Ma, X. & Wang, D. Novel mutations of DAX1 (NR0B1) in two Chinese families with X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Mol. Genet. Metab. 97, 1063–1072. https://doi.org/10.1016/j.ymgme.2016.06.005 (2016).

26. Yu, T. This study was funded by the Medical Science and Technology Research Projects of Henan Province, China (2018020049) and Key R&D and Promotion Projects of Henan Province, China (192102310341). The authors would like to thank all participants of this study.

Acknowledgements

This study was funded by the Medical Science and Technology Research Projects of Henan Province, China (2018020049) and Key R&D and Promotion Projects of Henan Province, China (192102310341). The authors would like to thank all participants of this study.

www.nature.com/scientificreports/
Author contributions
D.B.F. conceived the study and designed the experiments. D.B.F. and L.L. performed the experiments. D.B.F.
and H.H.Z. analyzed the data. D.B.F. and L.L. wrote the manuscript. All authors read and approved the final
manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-021-95642-y.

Correspondence and requests for materials should be addressed to D.-B.F.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021